Author Interviews, Gender Differences, Mental Health Research, Race/Ethnic Diversity / 07.12.2025

[caption id="attachment_71691" align="alignleft" width="150"]MedicalResearch.com Interview with:Alexa T. Diianni, MBS Department of Medical Education Geisinger College of Health Sciences Scranton, PA 19409 MedicalResearch.com: What is the background for this study? During a previous study, my research team and I examined the financial conflicts of interest (COIs) between industry and academia- namely those that exist between authors of The American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM), and industry (1). The DSM is a diagnostic tool widely used for the diagnosis of psychiatric disorders, and is thus of interest in assessing COIs (1,2). We previously found that authors of the DSM-5-TR had received over $14.2m in undisclosed payments from industry (1). Our current study examines the gender and geographic disparities of the DSM-5-TR authors, in relation to these payments. While previous investigations have evaluated financial COIs in recent editions of the DSM (3,4), the demographic information of its authors has not yet been examined. Equitable representation of DSM authors is paramount as this manual serves a diverse population across the United States and beyond. It is important that the authorship of this manual be reflective of the population in which it serves, as there have been reported differences in both the type and prevalence of psychiatric care sought out by gender, as well as varying clinical treatment by geographic location (5-8). MedicalResearch.com: What are the main findings? Of the 225 physicians that were identified as contributors to the DSM-5-TR task force, panels, and cross-cutting review groups, 116 contributors met the inclusion criteria of being a US-based physician with an active National Provider Identifier. Of these included individuals, 69.8% were men and 30.2% were women. Just three states accounted for 43.9% of contributors (New York, 17.2%; California, 14.7%; Massachusetts, 12.1%), while twenty-three states received no author representation. Of the total $14.6m in industry payments received by contributors, $13.2m (91.8%) was received by male contributors. Male contributors thus received an average of $287k in payment, while female contributors received $72k. MedicalResearch.com: What should readers take away from your report? Due to the prevalent use of the DSM, it is important that transparency regarding financial conflicts of interest exists, with COIs minimized moving forward to avoid implicit bias and pro-industry thought (1,9-15). Furthermore, it is important that future editions of the DSM be representative of the population in which it serves. This can be attained by selecting an adequate proportion of male and female contributors for the DSM, which may provide more robust perspectives on current diagnoses. Additionally, representation of contributors from all regions across the US will allow for a more diverse and informed perspective on diagnostic criteria, allowing for improved public health and patient care within the United States. MedicalResearch.com: What recommendations do you have for future research as a result of this study? As gender and geographic disparities were shown to be significant through this study, I believe it would be interesting to address additional areas of demographic disparities among authors. Additional areas to examine may include non-US-based physicians, non-MD/DO authors, as well as ethnic and racial disparities among authors. Finally, similar studies may be applied to additional clinical and diagnostic tools. Diagnostic manuals, such as the DSM, written by a diverse set of individuals, would provide unique perspectives that best reflect the population as a whole, and in turn, benefit patient care. For this reason, it is important that diagnostic manuals, such as the DSM, include a diverse set of authors that can provide adequate input regarding the patient population it serves. MedicalResearch.com: Is there anything else you would like to add? This research received no external funding. First author (AD) is employed by PerkinElmer, working on assignment at GlaxoSmithKline (2023-Present), outside of the submitted work; Last author (BP) contributed to an osteoarthritis research team supported by Pfizer and Eli Lilly (2019-21) and received grants from the Pennsylvania Academic Clinical Research Center, outside of the submitted work. New Paper Diianni AT, Davis LC, Piper BJ. Gender and geographic disparities among DSM-5-TR authors in relation to financial conflicts of interest and industry payments: cross-sectional analysis. BMJ Mental Health. 2025;28:e301913. https://doi.org/10.1136/bmjment-2025-301913 References: 1. Davis LC, Diianni AT, Drumheller SR, Elansary NN, D’Ambrozio GN, Herrawi F, Piper BJ, Cosgrove L. Undisclosed financial conflicts of interest in DSM-5-TR: cross sectional analysis. BMJ. 2024;384. 2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. 2022. 3. Cosgrove L, Krimsky S, Vijayaraghavan M, Schneider L. Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychother Psychosom 2006;75:154-60. doi:10.1159/000091772. Pmid:16636630 4. Cosgrove L, Krimsky S. A comparison of DSM-IV and DSM-5 panel members’ financial associations with industry: a pernicious problem persists. PLoS Med2012;9:e1001190. doi:10.1371/journal.pmed.1001190. Pmid:22427747 5. Piper BJ, Ogden CL, Simoyan OM, Chung DY, Caggiano JF, Nichols SD, et al. (2018) Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016. PLoS ONE 13(11): e0206100. https://doi.org/10.1371/journal.pone.0206100 6. Bareis N, Olfson M, Wall M, Stroup TS. Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United States. Psychiatric Services. American Psychiatric Publishing; 2022;73(5):492–500. https://doi.org/10.1176/appi.ps.202000932 7. Tedstone Doherty D, Kartalova-O'Doherty Y. Gender and self-reported mental health problems: predictors of help seeking from a general practitioner. Br J Health Psychol. 2010;15(Pt 1):213-28. 8. Terlizzi EP, Schiller, Jeannine S. Mental health treatment among adults Aged 18–44: United States, 2019–2021. Report. Hyattsville, MD: National Center for Health Statistics; 2022. 9. Grande D, Frosch DL, Perkins AW, Kahn BE. Effect of exposure to small pharmaceutical promotional items on treatment preferences. Arch Intern Med. 2009;169(9):887-893. doi:10.1001/archinternmed.2009.64 10. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. In: Graham R, Mancher M, Miller Wolman D, et al., eds. Clinical Practice Guidelines We Can Trust. Washington (DC). National Academies Press, 2011, https://www.ncbi.nlm.nih.gov/books/NBK209539/?report=classic, doi:10.17226/13058. 11. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283:373-80. doi:10.1001/jama.283.3.373. Pmid:10647801 12. Moore DA, Tanlu L, Bazerman MH. Conflict of interest and the intrusion of bias. Judgm Decis Mak 2010;5:37-53. doi:10.1017/S1930297500002023 13. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003;290:252-5. doi:10.1001/jama.290.2.252. Pmid:12851281 14. Nejstgaard CH, Bero L, Hróbjartsson A, et al. Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review. BMJ 2020;371:m4234. doi:10.1136/bmj.m4234. Pmid:33298430 15. Thompson DF. The challenge of conflict of interest in medicine. Z Evid Fortbild Qual Gesundhwes 2009;103:136-40. doi:10.1016/j.zefq.2009.02.021. Pmid:19554887 Alexa T. Diianni[/caption] MedicalResearch.com Interview with: Alexa T. Diianni, MBS Department of Medical Education Geisinger College of Health Sciences Scranton, PA 19409 MedicalResearch.com: What is the background for this study? Response: During a previous study, my research team and I examined the financial conflicts of interest (COIs) between industry and academia- namely those that exist between authors of The American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM), and industry (1). The DSM is a diagnostic tool widely used for the diagnosis of psychiatric disorders, and is thus of interest in assessing COIs (1,2). We previously found that authors of the DSM-5-TR had received over $14.2m in undisclosed payments from industry (1). Our current study examines the gender and geographic disparities of the DSM-5-TR authors, in relation to these payments. While previous investigations have evaluated financial COIs in recent editions of the DSM (3,4), the demographic information of its authors has not yet been examined. Equitable representation of DSM authors is paramount as this manual serves a diverse population across the United States and beyond. It is important that the authorship of this manual be reflective of the population in which it serves, as there have been reported differences in both the type and prevalence of psychiatric care sought out by gender, as well as varying clinical treatment by geographic location (5-8). 
Allergies, Author Interviews, Dermatology / 06.12.2025

[caption id="attachment_71677" align="alignleft" width="200"]Dr. Shaila Gogate, MDColorado Allergy & Asthma Centers Allergist REMIX-1/-2 Investigator  Dr. Gogate[/caption] MedicalResearch.com Interview with: Dr. Shaila Gogate, MD Colorado Allergy & Asthma Centers Allergist REMIX-1/-2 Investigator MedicalResearch.com: What is the background for this study? What are the main findings?
  • The Phase III REMIX-1/-2 studies were randomized, double-blind, placebo-controlled studies assessing the efficacy and safety of oral  remibrutinib 25 mg twice daily or placebo over a 24-week double-blind period, followed by a 28-week open-label remibrutinib treatment period.
  • The purpose of this pooled analysis was to examine the early and long-term efficacy data of remibrutinib vs. placebo over time, looking at the mean percentage change from baseline (CFB) in weekly scores of disease activity (UAS7), itch severity (ISS7) and hives severity (HSS7) over 52 weeks. This analysis demonstrated that remibrutinib showed reductions in urticaria symptoms vs. placebo as early as week 1:
    • 38.4% vs. 10.3% in UAS7
    • 37.0% vs. 9.8% in ISS7
    • 39.8% vs. 10.1% HSS7
  • Greater reductions vs. placebo were seen over 24 weeks and results were observed in the open-label period through week 52 in all remibrutinib-treated patients (including those transitioned from placebo).
Allergies, Author Interviews, Dermatology / 05.12.2025

MedicalResearch.com Interview with: [caption id="attachment_71671" align="alignleft" width="133"]Dr. Giselle Mosnaim MD MSAllergist Division of Allergy and Immunology Department of Medicine Northshore University Health System REMIX-1/-2 Investigator Dr. Mosnaim[/caption] Dr. Giselle Mosnaim MD MS FACAAI Allergist Division of Allergy and Immunology Department of Medicine Northshore University Health System REMIX-1/-2 Investigator MedicalResearch.com: What is the background for this study? What are the main findings? Response: Chronic spontaneous urticaria is a debilitating condition significantly affecting patient quality of life and is characterized by the presence of itch, hives, and/or angioedema (swelling) lasting for greater than 6 weeks, without identifiable trigger. Second-generation H1-antihistamines at standard doses are recommended as first-line treatment for patients with chronic spontaneous urticaria, and can be up-dosed to 4 times the standard dose. However, over 50% of patients continue to have symptoms despite this therapy. Both Remibrutinib and Dupilumab are FDA-approved for the treatment of chronic spontaneous urticaria in adult patients (Remibrutinib ≥ 18 years old and Dupilumab ≥ 12 years old) who remain symptomatic despite second-generation H1-antihistamine treatment. The RECLAIM study is an ongoing head-to-head randomized controlled trial comparing the efficacy of Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, and Dupilumab, an injectable anti-interleukin-4 and anti-interleukin-13 inhibitor, at early timepoints (4 weeks and earlier) when administered as an add-on therapy in adults with moderate to severe chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines.
Author Interviews, Psychedelics / 03.12.2025

Editor’s note: Please remember psychedelics remain illegal in most of the US and are not FDA tested or approved. Psychedelics and hallucinogens can have serious short and long term side effects and should be utilized only with careful medical supervision. [caption id="attachment_71656" align="alignleft" width="200"]dr-daniel-kruger Dr. Kruger[/caption] MedicalResearch.com Interview with: Daniel J. Kruger, PhD Population Studies Center, Institute for Social Research University of Michigan MedicalResearch.com: What is the background for this survey? Response: Multiple studies indicate that psychedelic use is at an all-time high. There are hundreds of clinical trials on the use of psychedelics and psychedelic-derived compounds for potential mental health benefits. Popular books like Michael Pollan’s “How to Change Your Mind” have raised public awareness of these substances and their potential benefits. Legislative changes in some areas have liberalized psychedelic access for therapy and personal use. Still, the vast majority of those who use psychedelics will use them outside of regulated, supervised settings. People are reporting both amazing therapeutic benefits as well as adverse experiences, and sometimes detrimental effects that last well beyond the trip. This study aimed to develop a risk-reduction resource to facilitate safe and successful psychedelic experiences outside of regulated settings. We employed a community-based approach to crowdsource practical recommendations for first-time psychedelic experiences from the psychedelic community.
Cannabis / 26.11.2025

Editor’ note:  Cannabis and THCA/HEMP CBD products should have an active ingredient list on the container and have a Certificate of Analysis (COA)/Discuss your use of THC, Cannabis or CBD products with your health care provider.  Dosing of CBD is variable, especially since it is not FDA regulated. Cannabis/CBD may interfere with other medications and should not be used in individuals with certain health conditions, including liver issues. CBD skin care products can be absorbed through the skin and have similar effects. Do not use Cannabis products including edibles and CBD if you are pregnant, nursing or may become pregnant. Do not use cannabis products if driving or operating difficult or dangerous machinery. Children should not be exposed to cannabis or CBD products. Boom of Modern-Day Wellness Helpers.png Wellness today looks very different from what it was even five years ago. People now want relief that is quiet, simple, and easy to integrate into a busy lifestyle. This shift has led to the rise of subtle, modern-day wellness tools and products designed to support balance without demanding time or major daily changes. Innovations such as CBD patches wholesale, clean CBD liquid wholesale solutions, and fast-acting CBD shots in the UK demonstrate just how far the wellness landscape has evolved. For many consumers, the new goal isn’t dramatic transformation; it’s small, consistent improvements that feel effortless. The modern consumer is more informed, more selective, and more focused on practicality than ever before. Instead of relying on complicated wellness rituals or lengthy sessions of self-care, people now seek micro-relief solutions that deliver genuine benefits in minutes, not hours. This is where subtle aids like patches, liquids, shots, and micro-dose formats have changed the game.

Why Subtle Wellness Is So Popular Today

People don’t want to overhaul their routines they want products that slip into daily life without friction. Subtle wellness solutions work because they remove barriers: no prep time, no steep learning curve, no noticeable interruption. Whether someone is at work, travelling, or winding down at home, these aids offer an easy way to regain balance. Today’s wellness movement is built on three traits:
  1. Convenience
Consumers want tools that don’t demand major adjustments. Subtle wellness allows support anytime, anywhere.
  1. Discretion
Not everyone wants their wellness routines on display. Patches, liquids, and shots offer quiet ways to feel better without drawing attention.
  1. Speed
Stress, tension, and burnout don’t wait for scheduled rituals. People need fast-acting relief they can count on instantly. This is exactly why CBD-focused products have grown so quickly; they fit all three criteria.
Health Care Systems, Technology / 26.11.2025

[caption id="attachment_71530" align="aligncenter" width="500"]healthcare-it-strategy Photo by Field Engineer[/caption]

Introduction

The server is down. Again. Your team is idle, customers can't be served, and you're on the phone, again, paying for an emergency fix. This cycle of technology fire-fighting is an all-too-common reality for small business owners. IT often feels less like a tool for success and more like a source of unpredictable costs and frustrating disruptions. But what if your technology could prevent problems instead of just reacting to them? This isn't just wishful thinking; it's a strategic necessity in today's competitive landscape. The difference between a business that struggles with constant IT issues and one that thrives is the shift from a reactive to a proactive approach. This article explains how a proactive IT strategy, powered by cutting-edge solutions, transforms technology from a costly liability into a powerful asset for sustainable business growth and security.

Key Takeaways

  • Reactive "break-fix" IT is a cycle of unpredictable costs and disruptive downtime, while proactive IT focuses on prevention, strategic planning, and operational stability.
  • The tangible benefits of a proactive approach include significant long-term cost savings, drastically reduced security risks, and a technology infrastructure that can scale with your healthcare business.
  • "Cutting-edge" tools like advanced cybersecurity and cloud services are most effective when implemented as part of a holistic strategy, not just as standalone technology purchases.
  • Partnering with a managed IT provider is the most effective way for any small business, including healthcare firms, to successfully implement and maintain a proactive technology roadmap.
Author Interviews, Cannabis, JAMA / 25.11.2025

Editor’ note:  Cannabis and THCA/HEMP CBD products should have an active ingredient list on the container and have a Certificate of Analysis (COA). Discuss your use of THC, Cannabis or CBD products with your health care provider.  Dosing of CBD is variable, especially since it is not FDA regulated. Cannabis/CBD may interfere with other medications and should not be used in individuals with certain health conditions, including liver issues. CBD skin care products can be absorbed through the skin and have similar effects. Do not use Cannabis products including edibles and CBD if you are pregnant, nursing or may become pregnant. Do not use cannabis products if driving or operating difficult or dangerous machinery. Children should not be exposed to cannabis or CBD products. [caption id="attachment_71501" align="alignleft" width="157"]Dr. Swartz Dr. Swartz[/caption] MedicalResearch.com Interview with: James A. Swartz, PhD Professor, Jane Addams College of Social Work University of Illinois Chicago MedicalResearch.com: What is the background for this study? Response: For the past 5 1/2 years, my project team has been charged with monitoring the public health effects of adult cannabis use legalization in Illinois. To fulfill that obligation, we have monitored state data and have tried to keep informed about ongoing research on cannabis legalization and public health. Cannabinoid hyperemesis syndrome (CHS) rose to the surface of this continual monitoring through a growing number of publications indicating the prevalence of this condition was on the rise and clinical case reports. As context, for any readers unfamiliar with the clinical syndrome, CHS is a paradoxical reaction to long-term, heavy cannabis use. Instead of relieving nausea, cannabis in some people appears to trigger cycles of severe nausea, vomiting, and abdominal pain. Patients often present repeatedly to emergency departments, undergo extensive workups, and only much later does someone connect the dots and consider CHS. Resource use is substantial. CHS visits often involve repeat ED presentations, imaging, laboratory testing, and sometimes hospital admission. Even though CHS is rarely life-threatening, it is not a trivial condition from either the patient’s or the system’s perspective.

Most of the existing literature has been case reports, small series, or single-center studies. Those reports clearly show that CHS can be debilitating and is frequently misdiagnosed, but they don’t tell us much about the bigger picture:

  • How often Cannabinoid hyperemesis syndrome is showing up in emergency departments nationally
  • How those rates have changed over time, especially as cannabis policies and patterns of use have shifted
  • What the typical patient profile looks like at a population level

Our goal was to step back and use a large national emergency department database to describe CHS at scale in the United States from 2016 through 2022.

Cognitive Issues, ENT, Hearing Loss / 22.11.2025

Hearing is often described as a simple act of receiving sound, but in reality it’s a deeply interactive process. Every noise, voice, or melody you encounter sets off an intricate exchange between your ears and your brain. Your brain sorts through the chaos, interprets patterns, and gives meaning to what you hear. When hearing weakens, this seamless coordination becomes strained, and the brain must work harder to keep up. When sound input becomes faint or distorted, the brain starts compensating by trying to reconstruct what was missed. That extra mental effort drains cognitive resources that would normally support attention, memory, and comprehension. People may not notice the load they’re carrying until they begin feeling mentally tired, overwhelmed in conversation, or unable to follow speech in groups. Hearing loss also affects the brain’s auditory centers—the areas responsible for interpreting sound and supporting higher-level thinking skills. When these pathways receive less stimulation, they can weaken, which may influence broader cognitive functions over time. This connection helps explain why untreated hearing difficulties often coincide with challenges in focus, processing, or recall. Social behavior plays a role as well. When hearing becomes a struggle, many individuals gradually step back from group interactions or noisy environments. With fewer conversations and less meaningful auditory engagement, the brain loses important practice. This creates a circular pattern: difficulty hearing leads to less participation, which then reduces the brain’s exposure to the very stimulation that keeps it sharp.
Author Interviews / 20.11.2025

MedicalResearch.com Interview with: [caption id="attachment_71487" align="alignleft" width="150"]Kristen D. Krause Dr. Krause[/caption] Kristen D. Krause, PhD, MPH (she/her/hers) Assistant Professor, Department of Urban-Global Public Health Deputy Director, Center for Health, Identity, Behavior and Prevention Studies (CHIBPS) Rutgers School of Public Health Deputy Editor, Annals of LGBTQ Public and Population Health Deputy Editor, Behavioral Medicine MedicalResearch.com: What is the background for this study? Response: Young sexual minority men often face myriad challenges including stigma, heightened risk for mental health issues, and an increased likelihood of substance use. This study set out to shine a light on how ADHD symptoms might factor into these risks—a topic rarely examined directly in this population. MedicalResearch.com: What are the main findings? Response:  We found that ADHD symptoms are not only common, but they are associated with increased odds of both early and frequent substance use, spanning everything from cigarettes to alcohol and more illicit substances. These results don’t just fill a gap, they invite attention to a complex interplay of identity, mental health, and behavior.
Author Interviews, Cannabis, JAMA, Opiods / 13.11.2025

[caption id="attachment_71419" align="alignleft" width="150"]MedicalResearch.com Interview with:Victoria Bethel, MSN Department of Public Administration and Policy University of Georgia, Athens Victoria Bethel[/caption] MedicalResearch.com Interview with: Victoria Bethel, MSN Department of Public Administration and Policy University of Georgia, Athens   MedicalResearch.com: What is the background for this study? Response: From the same pool of commercially insured patients, we found that cannabis dispensary openings were associated with reduced opioid prescribing among patients with non-cancer pain. For this study, we examined whether cannabis dispensary openings were also associated with reduced opioid prescribing among commercially insured patients who do have a cancer diagnosis. Similar to patients without cancer, we estimated reductions in opioid prescribing after medical and recreational cannabis dispensaries open. These findings may suggest that patients who experience cancer pain are able to manage their pain with cannabis instead of requiring opioids, although we cannot directly observe substitution.
Author Interviews, Legal-Malpractice / 11.11.2025

[caption id="attachment_71373" align="aligncenter" width="500"]evidence-in-malpractice-cases Photo by Sora Shimazaki[/caption] Baltimore has long stood as a center of medical excellence. Yet even in a city with such a strong healthcare reputation, medical errors can and do occur—often leaving patients facing devastating consequences. When these mistakes lead to injury or worsening health, pursuing a medical malpractice claim becomes not just about compensation, but about accountability. However, proving that a healthcare provider acted negligently requires more than emotion—it demands clear, compelling evidence.  From detailed medical records and expert testimony to communication logs and hospital policies, each piece of proof helps build a credible case. A skilled Baltimore medical malpractice lawyer understands how to identify, preserve, and present this evidence effectively, ensuring that victims have the strongest possible foundation to seek justice within Baltimore’s complex legal and healthcare landscape.

Medical Records

At the heart of any malpractice case are medical records. They provide descriptions of your diagnoses, treatments, medications, and procedures that have been performed. By consulting these records, one can notice gaps or omissions in the care. Changes or incompleteness can put into question the quality of care rendered. It also corroborates the patient narrative.
Author Interviews, Mental Health Research, Schizophrenia / 07.11.2025

MedicalResearch.com Interview with: [caption id="attachment_71333" align="alignleft" width="100"]Ian Kelleher PhD, MB BCh BAO (Medicine)Professor of Child and Adolescent Psychiatry Academy of Medical Sciences Professor Institute for Neuroscience and Cardiovascular Research University of Edinburgh  Prof. Kelleher[/caption] Ian Kelleher PhD, MB BCh BAO (Medicine) Professor of Child and Adolescent Psychiatry Academy of Medical Sciences Professor Institute for Neuroscience and Cardiovascular Research University of Edinburgh MedicalResearch.com: What is the background for this study? What are the main findings? Response:  Schizophrenia is a severe mental illness associated with hallucinations, delusions and a marked decline in functioning. It usually begins in adulthood, in the 20s, but we know from recent research that as many as half of all individuals who develop schizophrenia had attended child and adolescent psychiatry services earlier in life for other mental health problems. That’s exciting because it suggests: maybe there’s something we could do to reduce risk of schizophrenia in adolescent psychiatry services. But, at present, we don’t have evidence that any intervention reduces schizophrenia risk in this clinical population. Lots of researchers are interested in the antibiotic doxycycline, and the structurally similarly minocycline, because it has potential neuroprotective effects. It crosses the blood brain barrier and seems to reduce inflammation and apoptosis (or programmed cell death). We think that excessive synaptic pruning may play a key role in the development of schizophrenia. In laboratory studies, doxycycline seems to reduce the level of synaptic pruning by its effect on the immune system. Some research suggests that even low dose exposure to doxycycline may lead to long-term effects in “dampening down” activity by microglia, the brain’s resident macrophages, which are central to the process of synaptic pruning.
Author Interviews, Caregiving / 07.11.2025

[caption id="attachment_71328" align="aligncenter" width="500"]caregiving-stages-of-life Freepik image[/caption] As individuals move through different stages of life, the level of support they require can shift along the way. From occasional assistance with daily tasks to full-time care, having access to flexible and tailored support ensures that people maintain independence, dignity, and comfort in their own homes. Understanding how care needs evolve can help families make informed decisions and feel confident that their loved ones are receiving the right level of support at the right time.

Early Stages: Occasional Support for Everyday Living

In the early stages of needing support, many people only require a small amount of help to remain independent. This could include assistance with light household duties, meal preparation, or companionship to prevent feelings of loneliness. These early interventions are often enough to make daily living more manageable without interrupting routines or independence. Regular check-ins offer reassurance for both the individual and their family, creating a foundation of trust that can be built upon if care needs increase. This stage is also an opportunity to establish a relationship with care professionals who can adapt their approach as requirements change. Building that familiarity early can make transitioning to more comprehensive care smoother and less overwhelming later on.
Author Interviews, Cosmetic Procedures / 05.11.2025

[caption id="attachment_71290" align="aligncenter" width="267"]How Long Do HIFU Results Last Photo by Anna Shvets[/caption] Did you know that HIFU technology was originally developed to treat prostate cancer before being adapted for facial rejuvenation? HIFU face lifting Singapore uses High-Intensity Focused Ultrasound to stimulate deep tissue collagen production, offering natural, long-lasting facial tightening without surgery. HIFU results typically develop gradually over 2–3 months and remain effective for 12–18 months in most patients. The treatment targets the SMAS (Superficial Musculo-Aponeurotic System) layer — the same layer manipulated during surgical facelifts — using precise ultrasound energy at depths of 1.5mm, 3.0mm, and 4.5mm beneath the skin surface. Immediate tissue tightening occurs due to thermal coagulation points, while the body’s natural healing response triggers neo-collagenesis — the production of new collagen fibers — over the next 12 weeks. The longevity of HIFU face lifting results depends on skin quality, collagen density, lifestyle, and the treatment protocol used.
Author Interviews, Cancer Research, JAMA, Weight Research / 02.11.2025

MedicalResearch.com Interview with: [caption id="attachment_71229" align="alignleft" width="125"]Dr. Bian Jiang Dr. Bian Jiang[/caption] Jiang Bian, PhD Associate Dean of Data Science Walther and Regenstrief Professor of Cancer Informatics Professor of Biostatistics & Health Data Science Adjunct Professor, Biomedical Engineering and Informatics Chief Data Scientist, Regenstrief Institute Chief Data ScientistCustomize & Schedule Social Media Posts Indiana University Health [caption id="attachment_71230" align="alignleft" width="125"]Serena Jingchuan Guo Dr. Serena Guo[/caption] Serena Jingchuan Guo, MD PhD Assistant Professor Department of Pharmaceutical Outcomes and Policy University of Florida College of Pharmacy [caption id="attachment_71231" align="alignleft" width="125"]Hao Dai, PhD Dr. Hao Dai[/caption] Hao Dai, PhD Postdoctoral Fellow Department of Biostatistics & Health Data Science Indiana University School of Medicine       MedicalResearch.com: What is the background for this study? What are the main findings? Response: Obesity and type 2 diabetes are both known to increase the risk of several cancers. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become very popular for both glycemic control and weight loss, but their long-term effects on cancer risk are still unclear. Using a large real-world dataset, we emulated a target trial comparing more than 43,000 GLP-1RA users to matched non-users. We found that GLP-1RA use was associated with a significantly lower overall cancer risk.
Uncategorized / 30.10.2025

[caption id="attachment_71194" align="alignleft" width="200"]Borja del Pozo Cruz, PhDDepartment of Sport Sciences Faculty of Medicine, Health, and Sport Sciences Universidad Europea de Madrid Dr. Del Pozo Cruz[/caption] MedicalResearch.com Interview with: Borja del Pozo Cruz, PhD Department of Sport Sciences Faculty of Medicine, Health, and Sport Sciences Universidad Europea de Madrid MedicalResearch.com: What is the background for this study? Response: We now have consistent evidence that taking around 7,000 to 10,000 steps per day is associated with substantially lower risks of death and cardiovascular disease. However, much less is known about how those steps are accumulated throughout the day. This question is particularly relevant for people who are mostly inactive, as their steps are often of lower intensity and accumulated in short, fragmented bouts. Understanding whether different step accumulation patterns have distinct health effects in this group is essential to refine physical activity recommendations and make them more inclusive.
Uncategorized / 29.10.2025

Understanding the Recovery Timeline

[caption id="attachment_71174" align="aligncenter" width="500"]Alcohol addiction pexels image Photo by Chris F[/caption] Recovery from alcohol addiction is a deeply personal journey. It doesn’t follow a one-size-fits-all timeline, because the process depends on factors such as the severity of addiction, length of use, mental health, and support systems. For many people—especially women—healing from alcohol addiction involves more than physical detox; it requires emotional growth, behavioral change, and rebuilding life balance. According to the National Institute on Alcohol Abuse and Alcoholism (NIAAA), recovery is best viewed as a long-term process of change that extends beyond abstinence. With consistent support, effective therapy, and accountability, long-term sobriety is absolutely achievable.
Uncategorized / 29.10.2025

MedicalResearch.com Interview with: [caption id="attachment_71167" align="alignleft" width="160"]Shemyia Smith, MBSDepartment of Medical Education Geisinger College of Health Sciences Scranton, PA 18509 Shemyia Smith[/caption] Shemyia Smith, MBS Department of Medical Education Geisinger College of Health Sciences Scranton, PA 18509 MedicalResearch.com: What is the background for this study? Response: Over the past several years, legal marijuana (also known as cannabis) use has substantially increased in many states and countries. Alongside this, more patients visit the emergency room and specialist with severe recurring nausea, vomiting, and abdominal pain. Often, this may be misdiagnosed since these symptoms are now known as Cannabinoid Hyperemesis Syndrome (CHS). Although CHS is now widely known, there is still a lot of uncertainty among clinicians about how to diagnose it confidently and manage it effectively.
Uncategorized / 29.10.2025

MedicalResearch.com Interview with: Prof. Francesca Levi-Schaffer and Ilan Zaffran, PhD candidate School of Pharmacy at the Hebrew University. MedicalResearch.com: What is the background for this study? Does this function of eosinophils use a different mechanism from their role in allergic reactions? Response: Eosinophils are best known as effector cells in allergic diseases such as asthma, but they are in fact multifunctional immune cells involved in host defense and homeostasis. In recent years, researchers have begun to explore how eosinophils interact with microbes and viruses, and even with fungal allergens. However, until now, no study had investigated the role of eosinophils in defense against pathogenic fungi such as Candida albicans. [caption id="attachment_71164" align="aligncenter" width="500"]eosinophils-candida-infections Eosinophils attacking C. albicans | Credit: Ilan Zaffran[/caption] Our work is the first to show that eosinophils can directly recognize and respond to this common opportunistic fungus. While the underlying mechanisms such as degranulation and cytokine release are fundamentally similar to those used during allergic responses, in this context they serve a protective antifungal role, expanding the known functional spectrum of eosinophils beyond allergy.  In addition, we discovered that eosinophils use the surface receptor CD48 to directly recognize the fungal adhesin Als6 on Candida albicans.
Uncategorized / 28.10.2025

Editor's note: This piece discusses mental health issues. If you have experienced suicidal thoughts or have lost someone to suicide and want to seek help, you can contact the Crisis Text Line by texting "START" to 741-741 or call the Suicide Prevention Lifeline at 800-273-8255. [caption id="attachment_71149" align="alignleft" width="200"]Massimiliano Orri, PhDAssistant Professor in the Department of Psychiatry McGill University Principal Investigator at the Douglas Research Centre  within the McGill Group for Suicide Studies. Dr. Massimiliano[/caption] MedicalResearch.com Interview with: Massimiliano Orri, PhD Assistant Professor in the Department of Psychiatry McGill University Principal Investigator at the Douglas Research Centre within the McGill Group for Suicide Studies. MedicalResearch.com: What is the background for this study? What types of medical conditions were associated with the early cannabis use? Response: We already know that cannabis use can be linked to both mental and physical health problems. But what about problems severe enough to require medical attention? In this study, we wanted to see whether young adults who had used cannabis during their teenage years were more likely to seek medical care for mental or physical health issues. Using medical service data allows us to look at more serious cases - those that required professional attention and were diagnosed by healthcare providers. It also helps us understand the broader impact of early cannabis use on the healthcare system
Author Interviews, Neurology / 22.10.2025

[caption id="attachment_71069" align="aligncenter" width="500"] Science Behind QEEG Brain Mapping Unsplash image[/caption] Understanding how the brain functions has always been one of science’s most fascinating and complex challenges. Today, advanced technologies like quantitative electroencephalography (QEEG) are making it possible to visualize brain activity in ways that were once unimaginable. Known simply as brain mapping, this innovative process offers a window into the intricate electrical patterns that define how we think, feel, and behave. By measuring and analyzing brainwave activity, QEEG is revolutionizing the way medical professionals diagnose and treat a wide range of neurological and psychological conditions.

What Is QEEG Brain Mapping?

QEEG Brain Mapping is a specialized form of electroencephalography (EEG) that quantifies and analyzes the brain’s electrical activity. Unlike a standard EEG, which simply records brainwave patterns, QEEG uses advanced algorithms to convert this raw data into detailed visual maps. These maps highlight areas of the brain that are overactive, underactive, or out of balance. Clinicians can then use these insights to better understand how different brain regions are functioning and interacting. The data from a QEEG is often compared to a large database of “normative” brain activity. This allows specialists to identify deviations that may be linked to conditions such as anxiety, ADHD, depression, traumatic brain injury, or cognitive decline. The ability to pinpoint these irregularities provides a more objective foundation for diagnosis and personalized treatment planning.
Author Interviews, Herpes Viruses, Inflammation, Vaccine Studies / 21.10.2025

[caption id="attachment_71064" align="alignleft" width="200"]Ali Dehghani, DODepartment of Medicine University Hospitals Cleveland Medical Center / Case Western Reserve University Presenting Author, IDWeek 2025 Dr. Dehghani[/caption] MedicalResearch.com Interview with: Ali Dehghani, DO Department of Medicine University Hospitals Cleveland Medical Center / Case Western Reserve University Presenting Author, IDWeek 2025 MedicalResearch.com: What is the background for this study? Response: Shingles (herpes zoster) is caused by reactivation of the varicella-zoster virus, which can inflame blood vessels and the nervous system. Evidence over the past decade has linked shingles to higher risks of heart attack, stroke, and dementia—but it was unclear whether the shingles vaccine might lessen those long-term effects.   [caption id="attachment_71061" align="aligncenter" width="500"]herpes-zoster-cdc-image CDC PHIL Image[/caption] MedicalResearch.com: What are the main findings? Response:  Using data from over 100 U.S. health systems, we followed adults age 50 and older for up to five years. We found that people who developed shingles had a 20–30% higher risk of cardiovascular events, vascular dementia, and death compared with similar adults without shingles. Those who had received the recombinant zoster vaccine (Shingrix) before their infection had substantially lower long-term risks—about 25% fewer major cardiac events, 40% lower early mortality, and nearly 50% less vascular dementia over time.
Author Interviews, Orthopedics, Pediatrics, PT-Rehabilitation / 20.10.2025

[caption id="attachment_71041" align="alignleft" width="200"]chris-church Chris Church[/caption] MedicalResearch.com Interview with: Chris Church MPT Director, Gait & Motion Analysis Laboratory Nemours duPont Hospital for Children MedicalResearch.com: What is the background for this study? Would you briefly describe the condition of clubfoot and arthrogryposis? Response: Clubfoot is a congenital foot deformity in which the child is born with their foot (or feet) are stiff and in position with the foot pointing down (equinus) and in (inverted).  Idiopathic clubfoot is a condition in which these children only have issues with their feet.  Arthrogryposis is a condition in which children have contractures in multiple parts of their body.  Children with Arthrogryposis often have clubfeet that are tighter and more difficult to treat than the more common idiopathic type. Idiopathic clubfoot is effectively corrected with a conservative treatment known as the Ponseti method. Recent studies have shown successful short-term correction using Ponseti treatment in the stiffer clubfoot associated with arthrogryposis, but there are few studies analyzing long-term results. This study compares outcomes of the Ponseti method in 10-year-old children with idiopathic clubfoot and clubfoot associated with arthrogryposis. MedicalResearch.com: Would you describe the Ponseti method? Does it require specialized or complicated training to implement treatment? Response: Clubfoot was treated with surgery in the past.  Now we use a more conservative treatment that is provided by pediatric orthopedic surgeons and physical therapists.  The Ponseti method involved serial casting in infancy, Achillies tenotomies, and prolonged use of bracing during sleep until age 5 years. [caption id="attachment_71050" align="alignleft" width="300"]ClubfootNemours Image Clubfoot
Nemours Image[/caption] [caption id="attachment_71051" align="alignleft" width="300"]Clubfoot Nemours Image Clubfoot
Nemours Image[/caption]            
Author Interviews, Diabetes, Kidney Disease, NYU, Weight Research / 20.10.2025

MedicalResearch.com Interview with: [caption id="attachment_71025" align="alignleft" width="225"]Michael A. Weintraub, MDClinical Assistant Professor Department of Medicine NYU Grossman School of Medicine Dr. Weintraub[/caption] Michael A. Weintraub, MD Clinical Assistant Professor Department of Medicine NYU Grossman School of Medicine MedicalResearch.com: What is the background for this study? Response: The study addresses a critical knowledge gap in diabetes management for dialysis patients. Of the 808,000 people on dialysis in the United States, approximately 60% have diabetes and would be eligible for GLP-1 receptor agonists (GLP-1 RAs). However, these medications have not been well-studied in this population because dialysis dependence is frequently an exclusion criterion in clinical trials.
Plastic Surgery, Surgical Research / 14.10.2025

Top Ways Plastic Surgery Enhances Health and Well-Being

Key Takeaways

  • Plastic surgery offers significant benefits for both physical health and mental well-being.
  • Addressing functional concerns can lead to a higher quality of life and improved self-image.
  • Working with Board-certified plastic surgeons ensures safety and personalized care.
  • Procedures can serve as motivation and support for maintaining healthier habits long term.
 

Table of Contents

  1. Introduction
  2. Enhancing Physical Functionality
  3. Boosting Self-Confidence and Mental Health
  4. Alleviating Chronic Pain
  5. Encouraging a Healthier Lifestyle
  6. Reducing Risk of Cardiovascular Issues
  7. Improving Vision
  8. Conclusion
Author Interviews, Cancer Research, Dental Research, JAMA, Microbiome, NYU, Pancreatic / 13.10.2025

[caption id="attachment_70956" align="alignleft" width="125"]Jiyoung Ahn, PhDProfessor of Population Health, NYU Grossman School of Medicine Associate Director for Population Science, NYU Perlmutter Cancer Center  NYU Langone Health New York, NY 10016 Dr. Jiyoung Ahn[/caption] MedicalResearch.com Interview with: Jiyoung Ahn, PhD Professor of Population Health, NYU Grossman School of Medicine Associate Director for Population Science, NYU Perlmutter Cancer Center NYU Langone Health New York, NY 10016 MedicalResearch.com: What is the background for this study? Response: About 10 years ago. we reported that people with poor oral health seem to have a greater risk of pancreatic cancer development.  We suspected that this could be due to oral microbiota.  More recently, animal studies, by other groups, showed that bacteria from the mouth can actually travel through saliva into the pancreas. But we didn’t know which exact species of bacteria or fungi might be involved in pancreas cancer development. We therefore conducted this large human study to examine the oral microbiome — including whole bacteria and fungi profiles in the mouth, and to see which bacteria and fungal taxa are associated with subsequent risk of pancreatic cancer development.
Addiction, addiction-treatment, Author Interviews, Opiods / 13.10.2025

MedicalResearch.com Interview with: [caption id="attachment_70953" align="alignleft" width="128"]Krisha S. Patel Krisha S. Patel[/caption] Krisha S. Patel Center For Pharmacy Innovation and Outcomes Geisinger College Health Sciences Scranton, PA MedicalResearch.com: What is the background for this study? Response: Hydromorphone is a powerful opioid medication approved for treating moderate to severe acute pain, as well as chronic pain that doesn’t respond to other treatments. One brand name is Dilaudid. It is much more potent than morphine, about 5 to 10 times stronger, and crosses the blood-brain barrier more efficiently. Hydromorphone comes in several forms, including oral powders, solutions, immediate- and extended-release tablets, and injectable options like intravenous, intramuscular, and subcutaneous. Like morphine, hydromorphone primarily targets the mu-opioid receptors, with some activity at delta receptors. Its higher fat solubility gives it a faster onset of action than morphine, though not as rapid as fentanyl. Due to its potency and risk for misuse and overdose, hydromorphone is typically prescribed only when other pain management options have failed. According to the RADARS StreetRx Program, in 2023, the black-market value of a 1 mg immediate-release tablet was about $15,000 annually, with extended-release tablets reaching $62,000 for a full-years supply. While previous studies have explored regional differences in the use of opioids like morphine, oxycodone, and codeine, hydromorphone has not been examined. This study aims to fill that gap by analyzing state-level and temporal trends in hydromorphone use across the US from 2010 to 2023. It draws on data from three major sources: the Drug Enforcement Administration’s Automated Reports and Consolidated Orders System (ARCOS), Medicaid, and Medicare Part D. By comparing these datasets, this report also explores how hydromorphone distribution and prescribing patterns have evolved over time.
Author Interviews, Dermatology, Hair Care, JAMA / 11.10.2025

[caption id="attachment_70946" align="alignleft" width="200"]dr-brett-king Dr. King[/caption] Brett King, MD, PHD  Dr. King was named an American Academy of Dermatology (AAD) “Patient Care Hero” for his work treating patients with severe alopecia areata Dermatology Physicians of Connecticut Fairfield, Connecticut MedicalResearch.com: What is the background for this study? Would you briefly explain the condition of Alopecia Areata? Response: Alopecia Areata (AA), an autoimmune form of hair loss, is common and its treatment has been revolutionized in the past ~3 years with approvals of 3 JAK inhibitors, bariticinib, ritlecitinib and deuruxolitinib. Prior to these approvals, off label treatments included the JAK inhibitors tofacitinib and ruxolitinib.   In a world of multiple treatments, especially when those treatments belong to the same medicine class, the question arises “If patients do not achieve treatment success with one medicine, might they achieve treatment success with another one?”